Novartis Pharmaceuticals

This program gives patients with serious non-small cell lung cancer access to the drug capmatinib when no other treatments are available and they cannot join a clinical trial. It is for people whose doctors have requested the drug and who have no satisfactory alternative therapy.…

This study tests whether inclisiran, an injectable medication, can reduce the amount of plaque buildup in the heart's arteries compared to a placebo. It includes 610 adults with non-obstructive coronary artery disease (blockages less than 50%) who are already taking statins. Part…

This study tests five different investigational drugs in 248 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful boils. The main goal is to see if these drugs reduce abscesses and inflamed bumps by at least half without increasing dra…

This study tests a drug called midostaurin, given with standard chemotherapy, for children with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). The goal is to see if the combination is safe and helps control the disease. Twenty-two children will receive the …

This study tests a combination of two experimental drugs (LEE011 and BYL719) with a standard hormone therapy (letrozole) in about 255 women with advanced ER+ breast cancer. The goal is to find safe doses and see if the triple combination can better control the cancer. Participant…

This study looks at the long-term safety and effects of the drug votoplam in people with Huntington's disease. About 144 participants who completed a previous votoplam study will receive the drug for up to 48 months. Researchers will monitor side effects and measure changes in br…

This study tests a new treatment called 177Lu-PSMA-617, a type of targeted radiation, in 469 men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if it delays cancer growth or improves survival compared to switching to an…

This study tests a new drug called HRO761, alone or combined with other treatments, in people with advanced solid tumors that have specific genetic markers (MSI-high or dMMR). The main goals are to find safe and effective doses and to see how well the drug shrinks tumors. About 1…

This study tests a new radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread. The drug seeks out and delivers radiation to cancer cells. The goal is to find a safe dose and see if it shrinks tumors. About 33 men with either hormone-sensitive or cas…

This study gives patients with advanced cMET-dependent solid tumors continued access to capmatinib, a targeted cancer drug, after completing a previous Novartis-sponsored trial. The main goal is to monitor long-term safety and side effects. About 29 participants who are already b…

This early-stage study tests a radioactive drug called [177Lu]Lu-DOTA-TATE in people with glioblastoma, an aggressive brain cancer. For newly diagnosed patients, it is given alongside standard radiation and chemotherapy. For those with recurrent cancer, it is given alone. The mai…

This study tests several combinations of the experimental drug LXH254 in people with advanced melanoma that has a BRAF or NRAS gene change and has stopped responding to earlier treatments. About 134 adults and teens (12 and older) will receive one of the drug combos to see if the…

This study tests whether adding iptacopan to standard treatment helps people with active ANCA-associated vasculitis (a rare autoimmune disease that inflames blood vessels) achieve and maintain remission. About 84 adults with newly diagnosed or relapsed disease will receive iptaco…

This study tests whether adding ianalumab to the standard drug eltrombopag can help adults with primary immune thrombocytopenia (ITP) who did not get better with steroids. ITP causes low platelet counts, leading to bruising and bleeding. The trial involves 152 participants and me…

This study tests whether adding alpelisib to standard hormone therapy (fulvestrant) helps control advanced breast cancer in people with a PIK3CA gene mutation. It includes 234 men and postmenopausal women whose cancer worsened after prior treatments. The goal is to see if the com…

This phase 3 trial tests whether a personalized cell therapy called tisagenlecleucel (a CAR-T treatment) works better than standard treatments for adults with follicular lymphoma that has come back or stopped responding after at least two prior therapies. About 109 participants w…

This early-phase study tests an experimental oral drug called IAG933 in adults with advanced mesothelioma or other solid tumors that have certain genetic changes. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 137 partici…

This study tests a drug called inclisiran in about 1,590 Chinese adults with coronary heart disease who still have high LDL (bad) cholesterol despite taking statins. Participants receive either inclisiran or standard care, and researchers check how much LDL drops over one year. T…

This study looks at how well the drug ofatumumab (Kesimpta®) works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday medical practice in Italy. About 379 adults who are already starting the drug will be followed for 12 months to see how many relapses they …

This study compares two ways of giving the drug ianalumab to adults with rheumatoid arthritis, Sjögren's disease, or lupus. One group gets one injection from a 2mL auto-injector, the other gets two separate 1mL shots. The goal is to see if the single injection works just as well …

This study tests a new gene therapy, CPK850, for people with a rare inherited eye disease called RLBP1 retinitis pigmentosa, which causes progressive vision loss and trouble seeing in the dark. The treatment is given as a single injection under the retina to deliver a working cop…

This program provides siponimod, a medication that helps control disease activity, to adults with secondary progressive multiple sclerosis who have no satisfactory alternative treatments. Patients must have active disease and a doctor's request. The goal is to manage the conditio…

This study allows cancer patients who were already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access to the treatment and monitor how long patients stay on it, as well as any side effects. Only 22 patien…

This study watches 106 people with relapsing multiple sclerosis in Austria to see if starting the drug Ofatumumab (Kesimpta) earlier makes a difference compared to starting it later. Over 2 years, researchers track how well the drug controls relapses, brain lesions, and disabilit…

This study tests a new treatment called rapcabtagene autoleucel (YTB323) for adults with several types of blood cancer, including chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. The treatment uses a patien…

This program provides access to the drug ceritinib for people with serious ALK-positive tumors or non-small cell lung cancer who have no other treatment options and cannot join a clinical trial. It is only available through a doctor's request and aims to offer potential benefit w…

This early-phase study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, melanoma, and kidney cancer. The main goal is to find a safe dose and understand side effects. About 126 participants will take part to see if the treatm…

This study tests an experimental drug called ARV-766, taken as a pill, for men with metastatic prostate cancer that has spread. The drug is given alone or with another medication (abiraterone). The goal is to see if it is safe and can shrink tumors or lower PSA levels. About 152 …

This study tests whether eltrombopag, a drug that boosts platelet production, can help adults with lower-risk myelodysplastic syndromes (MDS) who regularly need platelet transfusions. About 36 participants in Japan will receive either eltrombopag or a placebo to see if they can g…

This study follows 4 people with sickle cell disease who already received a gene-edited cell therapy called OTQ923. Researchers will check for delayed side effects, such as new cancers or blood disorders, and measure how long the therapy's benefits last. The goal is to understand…

This early-phase study tests an experimental drug called IDH305 in people with advanced cancers that have a specific genetic change (IDH1R132 mutation). The main goals are to find the safest dose and to check for side effects. About 166 adults with various advanced tumors are tak…

This study tests whether adding a new drug (pelabresib) to the standard treatment (ruxolitinib) works better than the standard treatment alone for people with myelofibrosis, a rare bone marrow disorder. About 430 adults who have not received prior JAK inhibitor therapy will take …

This study tests a new drug called JDQ443 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation). The drug is given alone as the first treatment. The study includes two groups: those with very low PD-L1 levels and those with higher PD-L1 plus …

This study tests a radioactive drug (lutetium-177 vipivotide tetraxetan) alone or combined with newer hormone therapy in 49 men with a specific type of prostate cancer that has stopped responding to standard hormone treatment but has not yet spread to bones or organs on scans. Th…

This study tests a drug called asciminib in people with chronic-phase chronic myeloid leukemia (CML). It includes patients who have already tried one other treatment and those newly diagnosed. The goal is to see if the drug can reduce cancer cells to very low levels. Participants…

This study tests a new maintenance dosing schedule for ofatumumab, a drug used to control relapsing multiple sclerosis (MS). Researchers want to see if the new schedule works as well as the current one in terms of drug levels in the blood, safety, and side effects. The study invo…

This study tests a combination of two drugs (alpelisib and fulvestrant) in 24 Japanese men and postmenopausal women with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that worsened after prior hormone therapy. The goal is to see if the combination…

This study tests the safety and early effectiveness of adding another drug (INC280, trametinib, ribociclib, gefitinib, or LXH254) to EGF816 for adults with advanced EGFR-mutant non-small cell lung cancer. About 105 participants will receive one of these combinations. The goal is …

This study looks at the long-term safety and effectiveness of remibrutinib, an experimental drug, for adults with chronic spontaneous urticaria (CSU) — a condition causing frequent hives and itching without a clear trigger. About 696 participants who completed earlier phase 3 tri…

This study tests whether adding alpelisib to standard fulvestrant therapy can slow cancer growth in Chinese men and postmenopausal women with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that worsened after prior hormone therapy. About 69 partici…

This study follows children aged 6 to 17 with moderate-to-severe plaque psoriasis who are taking secukinumab. Researchers want to see how long patients stay on the drug and how well it controls their symptoms. The study does not test a new treatment but observes real-world use of…

This study offers continued access to the drug ribociclib for people with metastatic breast cancer who are already taking it and seeing benefits in a previous Novartis study. The main goal is to monitor long-term safety and side effects. About 134 participants will be followed wh…

This study looks at whether taking two drugs, dabrafenib and trametinib, after surgery can help prevent melanoma from returning in Chinese patients with a specific gene change (BRAF V600). The treatment is given to people with stage III melanoma that has been completely removed. …

This study looks at the long-term safety of a drug called secukinumab for people with polymyalgia rheumatica (PMR), a condition that causes pain and stiffness. About 161 adults who finished a previous secukinumab study and had a relapse can join. The main goal is to track side ef…

This study tests a radioactive drug (Lu-PSMA-617) against a switch to another hormone therapy in Chinese men with advanced prostate cancer that has spread and stopped responding to treatment. The goal is to see if the radioactive drug can delay cancer growth better than changing …

This study tests a drug called JDQ443, alone or with other treatments, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and can shrink tumors. About 344 adults with lung, colorectal, or other cancers who have tri…

This study tests a drug called MAS825 in people with rare genetic diseases that cause severe inflammation. The goal is to see if the drug can prevent sudden flare-ups of symptoms. The trial involves 17 participants and uses a placebo for comparison.

This study tests whether adding the drug alpelisib to standard maintenance therapy (trastuzumab and pertuzumab) can delay cancer growth in people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation). About 19 participants who have already…

This large phase 3 trial is testing whether adding the drug ribociclib to standard hormone therapy can help prevent breast cancer from returning in people with hormone receptor-positive, HER2-negative early breast cancer. Over 5,000 women and men are participating. The study comp…

This study observes 600 adults with heart disease who are taking a new cholesterol-lowering drug called inclisiran alongside their usual medications. Researchers will track how much their bad cholesterol (LDL-C) drops and if they reach recommended targets. The goal is to see how …

This early-phase study tests a new drug, [177Lu]Lu-NeoB, in people with glioblastoma, a serious brain cancer. For newly diagnosed patients, the drug is given alongside standard radiation and chemotherapy. For those whose cancer has returned, it is given alone. The main goal is to…

This study tests whether adding ianalumab to standard steroid treatment helps adults with primary immune thrombocytopenia (ITP) maintain a safe platelet count (≥30 G/L) longer. About 226 participants who recently responded to steroids will receive either ianalumab or a placebo al…

This study tests a new medicine called ianalumab for people with active lupus, an autoimmune disease that causes inflammation and damage. About 436 participants will receive either ianalumab or a placebo as monthly or quarterly shots, added to their usual treatments. The goal is …

This study tests a new drug, JDQ443, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. Participants have already tried platinum chemo and immunotherapy. The goal is to see if JDQ443 can be…

This phase 3 study tests whether remibrutinib, a new daily pill, works better than teriflunomide at reducing multiple sclerosis relapses and slowing disability. About 1,000 adults with relapsing MS will take one of the two drugs for a year or more. The goal is to see if remibruti…

This early-stage study tests a new type of radiation therapy for men with a rare and aggressive form of prostate cancer that has spread. The treatment uses special scans to find which targets are on the surface of the cancer cells, then delivers a radioactive drug directly to tho…

This study tests a drug called ianalumab in people with active Sjogren's syndrome, an autoimmune disease causing dry eyes and mouth. About 500 adults will receive either the drug or a placebo to see if it reduces disease activity and symptoms over 48 weeks. The goal is to find a …

This study tests the safety and effectiveness of combining two drugs, ceritinib and nivolumab, in adults with a specific type of advanced lung cancer called ALK-positive NSCLC. About 57 participants will receive the drug combination to find the best dose and see if tumors shrink.…

This study is for people with advanced solid tumors who are already taking the drug spartalizumab (alone or with other treatments) and are seeing benefits. The main goal is to keep checking for side effects and to allow continued access to the drug. About 120 participants will be…

This study tests a drug called alpelisib in children and adults with PROS, a rare condition that causes abnormal overgrowth of body tissues. The goal is to see if the drug can shrink these growths by at least 20%. Participants are randomly assigned to receive either alpelisib or …

This study looks at how well secukinumab works over the long term for people with moderate to severe hidradenitis suppurativa, a painful skin condition. About 700 adults who completed a previous year-long study will either continue or pause treatment to see if the response lasts.…

This study tests an experimental drug called GIA632 in adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it safely clears or nearly clears the skin compared to a placebo. About 34 participants will receive either the drug or a placebo, and results w…

This study tests a one-time treatment called tisagenlecleucel (a CAR-T cell therapy) in children and young adults aged 1 to 25 with high-risk B-cell acute lymphoblastic leukemia. Participants have small amounts of cancer remaining after initial chemotherapy. The therapy uses the …

This early-phase study tests a new drug (DKY709) alone or with another drug (PDR001) in adults with advanced solid tumors like lung cancer, melanoma, and breast cancer that have not responded to standard treatments. The main goal is to check safety and find the right dose. About …

This study compares two multiple sclerosis (MS) treatments in children aged 10 to 17: a daily pill (fingolimod) versus a weekly injection (interferon beta-1a). The goal is to see which better reduces relapses and brain lesions over two years. About 240 participants will be follow…

This study is testing a new treatment called 177Lu-PSMA-617 for Chinese men with a type of advanced prostate cancer that has spread and is no longer responding to hormone therapy or chemotherapy. The treatment delivers radiation directly to cancer cells, aiming to shrink tumors a…

This study tests an experimental drug called ianalumab in people with a rare blood condition where the immune system mistakenly destroys red blood cells (warm autoimmune hemolytic anemia). Participants must have tried at least one other treatment without success. The main goal is…

This study looks at the long-term safety of a drug called ianalumab for people with Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. About 612 participants who completed a previous year-long study will receive ianalumab for up to 3 more years. The goal is…

This study offers ongoing treatment with the drug ceritinib to people with ALK-positive cancers who were already benefiting from it in a previous Novartis study. The goal is to keep providing the medicine and monitor its long-term safety. About 233 participants will take part, an…

This study tests an experimental drug called BION-1301 in 383 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug can slow the loss of kidney function and reduce protein in the urine over two years. Participants receive ei…

This early-phase study tests a new drug called DFV890 in about 62 adults with certain bone marrow diseases, including lower-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The main goals are to check the drug's safety, find the best dose, and see …

This study tests two newer drugs, ofatumumab and siponimod, against an older one, fingolimod, in children aged 10 to 17 with multiple sclerosis. The goal is to see which medicine better prevents relapses and has fewer side effects. All participants will take one of the three drug…

This study follows 434 adults with moderate to severe hidradenitis suppurativa (HS) who are taking secukinumab, a medication that helps control the disease. Researchers will observe how patients adjust their dosing (increase or decrease) over two years and what factors influence …

This early-stage study tests a new drug called PIT565 in about 61 adults with relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia. The main goal is to check the drug's safety and find the best dose. Participants must have tried at least two p…

This study tests a new drug, [177Lu]Lu-DOTA-TATE, combined with standard chemotherapy and immunotherapy for people newly diagnosed with extensive stage small cell lung cancer. The goal is to find a safe dose and see if the combination helps people live longer. About 24 adults wil…

This study tests a new drug called BION-1301 in healthy people and adults with IgA nephropathy, a kidney disease. The goal is to check if the drug is safe and how the body processes it. About 103 participants will be involved in this early-stage trial.

This study monitors the long-term safety of Leqvio, a medication for people with very high cholesterol (familial hypercholesterolemia) or high cholesterol. About 585 participants are being observed for side effects and how well the drug controls their cholesterol levels. The goal…

This program gives adults with a specific type of advanced melanoma (BRAF mutation-positive) access to two targeted drugs, trametinib and dabrafenib, which work together to shrink tumors and control the disease. Participants must have melanoma that has spread or cannot be removed…

This study is for men with a type of advanced prostate cancer that has stopped responding to hormone therapy. It tests whether adding a radioactive drug (lutetium-177 vipivotide tetraxetan) to another hormone therapy is safe and works better than the radioactive drug alone. The g…

This study tests a new drug, remibrutinib, for adults with chronic inducible urticaria (hives triggered by things like cold, pressure, or heat) that antihistamines don't control. About 362 participants will receive either the drug or a placebo for 52 weeks to see if it reduces it…

This study looks at the safety and effectiveness of the drug everolimus (Votubia) in Taiwanese adults with tuberous sclerosis complex who have kidney tumors called angiomyolipomas. Four participants will take the drug and be monitored for side effects and tumor shrinkage. The goa…

This study tests an experimental drug called ianalumab in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants have already tried steroids and another platelet-boosting drug. The goal is to…

This study looks at whether people with a type of spinal arthritis (non-radiographic axial spondyloarthritis) who are in remission need to keep taking secukinumab to avoid flare-ups. About 240 adults will either continue the drug or switch to a placebo to see who stays flare-free…

This study tests whether adding an experimental drug (JSB462) to a standard targeted radiation therapy (lutetium-177) works better than the radiation therapy alone for men with a specific type of advanced prostate cancer that no longer responds to hormone therapy. About 138 men w…

This study tracks 107 adults with moderate to severe hidradenitis suppurativa (HS) who are taking secukinumab as part of their normal care. Researchers want to see how well the drug reduces skin abscesses and tunnels in everyday practice. The goal is to understand real-world effe…

This study checks the long-term safety of the drug ruxolitinib (given alone or with panobinostat) in people with certain blood or immune conditions like myelofibrosis, polycythemia vera, graft-versus-host disease, acute myeloid leukemia, or thalassemia. Participants had already b…

This early-stage trial tests a treatment called YTB323 in about 21 adults with severe lupus that hasn't responded to other therapies. The goal is to see if it is safe and can help control the disease. Participants receive the therapy and are followed for side effects and how long…

This study tests a single dose of an experimental drug called TIN816 in 320 adults in intensive care with sepsis-related acute kidney injury. The goal is to see if the drug can help the kidneys recover better than a placebo. Researchers will measure kidney function over the first…

This study is for people with advanced solid tumors (like lung or colorectal cancer) that have a specific genetic change called KRAS G12C. It tests a new drug, JDQ443, combined with other treatments to see if they are safe and can shrink tumors. About 74 adults will take part. Th…

This study tests whether a new drug called remibrutinib works better than an existing medication, teriflunomide, for people with relapsing multiple sclerosis (RMS). About 1,000 adults aged 18 to 55 with RMS are taking part. The main goal is to see if remibrutinib reduces the numb…

This study looks at the long-term safety of iptacopan in people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. About 208 adults who completed earlier iptacopan trials will continue taking the drug and be monitored for side effects and how well it controls …

This study aimed to test two targeted radiation drugs (AAA602 and AAA802) given before surgery for men with high-risk prostate cancer that had spread to nearby lymph nodes. The goal was to see if the drugs could shrink the cancer and delay its return after the prostate and lymph …

This study tests a drug called inclisiran in over 17,000 people with heart disease. The goal is to see if it can prevent major heart problems like heart attacks, strokes, or heart-related death. Participants already take strong statins and have high LDL cholesterol. The drug is g…

This program gives eligible patients with polycythemia vera (a rare blood cancer causing too many red blood cells) access to the drug ruxolitinib. It is for people aged 12 and older who cannot take or have stopped responding to standard treatments like hydroxyurea. The goal is to…

This study tests a drug called pelacarsen in over 8,000 people with high levels of lipoprotein(a) — a genetic risk factor for heart disease. Participants already have heart disease and receive either the drug or a placebo. The goal is to see if pelacarsen can reduce major heart p…

This study tests a new daily pill (asciminib) against an older one (nilotinib) in adults newly diagnosed with a type of leukemia called CML. The main goal is to see if patients stay on asciminib longer because it causes fewer side effects. About 568 participants will take one of …

This study tests a drug called inclisiran in about 345 Asian patients with high cholesterol and heart disease or high risk for it. The drug is given as an injection alongside standard statin therapy. The main goal is to see if it safely lowers 'bad' LDL cholesterol more than a pl…

This study tracks 847 adults with high cholesterol or mixed dyslipidemia who are taking inclisiran along with other cholesterol medications. The goal is to see how much their LDL (bad) cholesterol drops after 10 months and how well they stick to the treatment. It is an observatio…

This study tests whether people with relapsing-remitting MS who have been stable for a year might do better by switching to the drug ofatumumab instead of staying on their current treatment. It also checks if a blood marker called neurofilament light (NfL) can predict who benefit…

This study tests an experimental drug called VHB937 in 251 people with early-stage ALS (symptoms started within 2 years). The goal is to see if VHB937 can slow the disease's progression, including preserving breathing and muscle function. Participants are randomly assigned to rec…

This study tests whether a combination of two drugs, dabrafenib and trametinib, can help adults with a specific type of advanced thyroid cancer (BRAF V600E mutation) that no longer responds to radioactive iodine or other targeted therapies. About 153 participants will receive eit…

This study looks at the long-term safety of the drug everolimus in people with tuberous sclerosis complex (TSC) who have hard-to-control seizures. Participants had already been taking everolimus in an earlier study and were still benefiting from it. The main goal is to track side…

This study tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy can help men with prostate cancer that has spread. About 1,145 men took part across 20 countries. The goal is to see if the combination delays cancer growth and improves surviva…

This study follows about 1,800 people with relapsing multiple sclerosis who have already taken ofatumumab in a previous Novartis trial. Researchers want to see how safe and effective the drug is over the long term, including its effects on vaccines and COVID-19 immunity. Particip…

This study follows people with myelodysplastic syndromes or chronic myelomonocytic leukemia who already benefited from the drug sabatolimab in an earlier trial. The goal is to collect more safety information over time, not to test a new treatment. About 33 participants will conti…

This study tests a new medicine called ianalumab, given as a monthly shot, for people with active systemic lupus erythematosus (SLE). The goal is to see if adding ianalumab to standard treatments can better control lupus symptoms and reduce flares. About 288 participants aged 12 …

This study tests two doses of a drug called crizanlizumab against a placebo in 255 people aged 12 and older with sickle cell disease who have had painful vaso-occlusive crises. The goal is to see if the drug can lower how often these crises happen each year. Participants may also…

This study tests a new daily pill called asciminib against several standard treatments for adults newly diagnosed with a type of leukemia called CML. About 405 participants will be randomly assigned to receive either asciminib or a standard tyrosine kinase inhibitor (TKI) chosen …

This study tests a drug called ianalumab in people with active Sjogren's syndrome, an autoimmune disease that causes dry eyes and mouth. About 276 adults with a recent diagnosis will receive either the drug or a placebo. The goal is to see if ianalumab can reduce disease activity…

This study looks at the long-term safety and effectiveness of the drug alpelisib in children and adults with PIK3CA-related overgrowth spectrum (PROS), a rare condition that causes abnormal growth. All 41 participants had already taken alpelisib in a previous study. Researchers w…

This large Phase 3 study tests if a drug called inclisiran can prevent major heart problems like heart attacks and strokes in people at high risk who have never had one. Over 14,000 participants receive either inclisiran or a placebo every six months. The goal is to see if the dr…

This study follows 192 adults with hidradenitis suppurativa (HS) for 12 months after they start taking secukinumab. Researchers ask patients to rate their pain, oozing, and bad smell on a 0-10 scale to see if symptoms improve. The goal is to understand the real-world impact of th…

This study tests a new daily pill, remibrutinib, for adults with chronic spontaneous urticaria (long-term hives and itching) that antihistamines can't control. About 470 participants will receive either remibrutinib, a placebo, or an active control (omalizumab injections) for up …

This study follows 302 adults with multiple sclerosis in France who are starting a new treatment called ofatumumab. Researchers want to see how the drug affects their quality of life over 12 months, including daily activities, mood, and social relationships. Participants fill out…

This study looks at how satisfied adults with moderate to severe hidradenitis suppurativa (HS) are with their treatment and how their quality of life changes after starting secukinumab. About 48 participants in the United Arab Emirates will fill out questionnaires over a short pe…

This study looks at 500 adults in Romania with heart failure who are taking Entresto. Researchers want to see if patients are also getting other recommended heart medications. The goal is to understand real-world treatment patterns and how well they follow official guidelines.

This study looks at how happy doctors and people with multiple sclerosis (MS) are with current treatments in everyday medical practice. Researchers will survey doctors and patients in several countries to understand satisfaction levels and what factors influence them. The goal is…

This study follows 201 adults with chronic myeloid leukemia who are taking the drug Scemblix (asciminib) as a third or later treatment option. The goal is to see how long patients stay on the drug and how well it works in everyday medical practice, not just in controlled trials. …

This study watches 242 people with high-risk polycythemia vera, a blood condition that raises the risk of dangerous blood clots. Researchers track things like blood pressure, weight, and lab tests to see which factors best predict clots. The goal is to help doctors identify who i…

This study looks at how well a combination of ribociclib and hormone therapy works in patients aged 65 and older with a certain type of advanced breast cancer (HR+/HER2-). The goal is to measure changes in quality of life and how long the treatment remains effective. About 329 pa…

This study watches 132 people with paroxysmal nocturnal hemoglobinuria (PNH) who are already taking Fabhalta. Researchers track infections, side effects, and what happens if treatment stops. No new drug is tested—the goal is to learn more about safety in everyday use.

This study looks at how much of the multiple sclerosis (MS) drug ofatumumab gets into breast milk. About 24 breastfeeding women with relapsing MS will provide milk samples after starting or restarting the drug. The goal is to help mothers and doctors understand the safety of brea…

This study follows 376 people with HR+HER2- advanced breast cancer in Russia to see how well ribociclib combined with hormone therapy or chemotherapy works in routine medical practice. It does not assign treatments or visits—just observes what happens. The main goal is to measure…

This study looks at how ribociclib, a targeted therapy, is actually used in everyday medical practice for women with a certain type of advanced breast cancer (HR+/HER2-). Researchers will follow about 1,000 women in France to see what doses and hormone therapy combinations doctor…